Construction and characterization of encapsidated poliovirus replicons that express biologically active murine interleukin-2

Journal of Interferon and Cytokine Research

Volumn 18, Issue 5, 1998, Pages 305-313

  Basak, Sukla ^a   McPherson, Sylvia ^b   Kang, Sunghyun ^c   Collawn, James F ^c   Morrow, Casey D ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYTOKINE; INTERLEUKIN 2; RNA; VIRUS PROTEIN; VIRUS VECTOR;

ARTICLE; HELA CELL; HUMAN; HUMAN CELL; NONHUMAN; PICORNAVIRUS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPLICON; VIRION; VIRUS CAPSID; VIRUS GENOME; VIRUS REPLICATION;

EID: 0031969510     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.1998.18.305     Document Type: Article

References (49)

1. RACANIELLO, V.R., and BALTIMORE, D. (1981). Molecular cloning of poliovirus DNA and determination of the complete nucleotide sequence of the viral genome. Proc. Natl. Acad. Sci. USA 78, 4887-4891.
2. KITAMURA, N., SEMLER, B.L., ROTHBERG, P.G., LARSEN, G.R., ADLER, C.J., DORNER, A.J., EMINI, E.A., HANECAK, R., LEE, J.J., VAN DER WERF, S., ANDERSON, C.W., and WIMMER, E. (1981). Primary structure, gene organization and polypeptide expression of poliovirus RNA. Nature (Lond.) 291, 547-553.
3. TOYODA, H., NICKLIN, M.J.H., MURRAY, M.G., ANDERSON, C.W., DUNN, J.J., STUDIER, F.W., and WIMMER, E. (1986). A second virus-encoded proteinase involved in proteolytic processing of poliovirus polyprotein. Cell 45, 761-770.
4. YPMA-WONG, M.F., and SEMLER, B. (1987). In vitro molecular genetics as a tool for determining the differential cleavage specificities of the poliovirus 3C proteinase. Nucleic Acids Res. 15, 2069-2088.
5. YPMA-WONG, M.F., and SEMLER, B.L. (1987). Processing determinants required for in vitro cleavage of the poliovirus P1 precursor to capsid proteins. J. Virol. 61, 3181-3189.
6. JORE, J., DEGUES, B., JACKSON, R.J., POUWELS, P.H., and ENGER-VALK, B.E. (1988). Poliovirus protein 3CD is the active protease for processing of the precursor protein P1 in vitro. J. Gen. Virol. 69, 1627-1636.
7. ANSARDI, D.C., PORTER, D.C., ANDERSON, M.J., and MORROW, C.D. (1996). Poliovirus assembly and encapsidation of genomic RNA. Adv. Virus Res. 46, 1-68.
8. SEMLER, B.L., DORNER, A.J., and WIMMER, E. (1984). Production of infectious poliovirus from cloned cDNA is dramatically increased by SV40 transcription and replication signals. Nucleic Acids Res. 12, 5123-5141.
9. RACANIELLO, V.R., and BALTIMORE, D. (1981). Cloned poliovirus complementary DNA is infectious in mammalian cells. Science 214, 916-919.
10. KAPLAN, G., and RACANIELLO, V.R. (1988). Construction and characterization of poliovirus subgenomic replicons. J. Virol. 62, 1687-1696.
11. CHOI, W.S., PAL-GHOSH, R., and MORROW, C.D. (1991). Expression of human immunodeficiency virus type 1 H1V-1 gag, pol and env proteins from chimeric HIV-1-poliovirus minireplicons. J. Virol. 65, 2875-2883.
12. PORTER, D.C., ANSARDI, D.C., and MORROW, C.D. (1995). Encapsidation of poliovirus replicons encoding the complete human immunodeficiency virus type 1 gag gene using a complementation system which provides the P1 capsid protein in trans. J. Virol. 69, 1548-1555.
13. mac239 Gag or envelope SU proteins. AIDS Res. Hum. Retrovir. 13, 53-62.
14. ANSARDI, D.C., PORTER, D.C., and MORROW, C.D. (1993). Complementation of a poliovirus defective genome by a recombinant vaccinia virus which provides P1 capsid precursor in trans. J. Virol. 67, 3684-3690.
15. ANSARDI, D.C., MOLDOVEANU, Z., PORTER, D.C., WALKER, D.E., CONRY, R.M., LOBUGLIO, A.F., McPHERSON, S., and MORROW, C.D. (1994). Characterization of poliovirus replicons encoding carcinoembryonic antigens. Cancer Res. 54, 6359-6363.
16. PORTER, D.C., WANG, J., MOLDOVEANU, Z., McPHERSON, S., and MORROW, C.D. (1997). Immunization of mice with poliovirus replicons expressing the C-fragment of tetanus toxin protects against lethal challenge with tetanus toxin. Vaccine 15, 257-264.
17. pol. Virus Res. 29, 241-254.
18. MOLDOVEANU, Z., PORTER, D.C., LU, A., McPHERSON, S., and MORROW, C.D. (1995). Immune responses induced by administration of encapsidated poliovirus replicons which express HIV-1 gag and envelope proteins. Vaccine 13, 1013-1022.
19. SONDEL, P.M. (1992). Interleukin-2. In: Cytokine Therapy. D.W. Galvani and J.C. Cawley (eds.) Cambridge, MA: Cambridge Unviersity Press, pp. 78-90.
20. STOPECK, A.T., and HERSH, E.M. (1997). Gene transfer into tumor cells in vitro: potential for adjuvant therapy of cancer. In: Adjuvant Therapy of Cancer S. E. Salmon (ed.) Philadelphia: Lippincott-Raven, vol. 8, pp. 9-17.
21. HEATH, A.W. (1995). Cytokines as immunological adjuvants. In: Vaccine Design: The Subunit and Adjuvant Approach. M.F. Powell and M.J. Newman (eds.) New York: Plenum Press, pp. 645-659.
22. SMITH, K.A. (1988). Interleukin-2: inception, impact and implications. Science 240, 1169-1176.
23. GOOD, M.F., POMBO, D., LUNDE, M.N., MALOY, W.L., HALENBECK, K., KOTHS, R., MILLER, L.H., and BERZOFSKY, J.A. (1988). Recombinant IL-2 overcomes genetic nonresponsiveness to malaria sporozoite peptides. Correlation of effect with biological activity of IL-2. J. Immunology 141, 972-977.
24. YOKOTA, T. (1985). Use of a cDNA expression vector for isolation of mouse interleukin-2 cDNA clones: expression of T-cell growth-factor activity after transfection of monkey cells. Proc. Natl. Acad. Sci. USA 82, 68-72.
25. KASHIMA, N. (1985). Unique structure of murine interleukin-2 as deduced from cloned cDNAs. Nature 313, 402-406.
26. ANSARDI, D.A., PORTER, D.C., and MORROW, C.D. (1991). Coinfection with recombinant vaccinia viruses expressing poliovirus P1 and P3 proteins results in polyprotein processing and formation of empty capsid structures. J. Virol. 65, 2088-2092.
27. GILLIS, S., FERM, M.M., OU, W., and SMITH, K.A. (1978). T cell growth factor: parameters of production and a quantitation microassay for activity. J. Immunol. 120, 2027-2032.
28. DOEDENS, J.R., and KIRKEGAARD, K. (1995). Inhibition of cellular protein secretion by poliovirus proteins 2B and 3A. EMBO J. 14, 894-907.
29. McLAUGHLIN, J.P., SCHOLM, J., KANTOR, J.A., and GREINER, J.W. (1996). Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2. Cancer Res. 56, 2361-2367.
30. ROSENTHAL, F.M., CRONIN, K., BANNERJI, R., GOLDE, D.W., and GANSBACHER, B. (1994). Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon cDNAs. Blood 83, 1289-1298.
31. CHEN, T.T., TAO, M.H., and LEVY, R. (1994). Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4 and granulocyte-macrophage colony-stimulating factor. J. Immunol. 153, 4775-4787.
32. FRANKEL, A., TAGGE, E., CHANDLER, J., BURBAGE, C., HANCOCK, G., VESELY, J., and WILLINGHAM, M. (1995). IL2-ricin fusion toxin is selectively cytotoxic in vitro to IL2 receptor-bearing tumor cells. Bioconj. Chem. 6, 666-672.
33. REISFELD, R.A., and GILLIES, S.D. (1996). Antibody-interleukin-2 fusion proteins: a new approach to cancer therapy. J. Clin. Lab. Anal. 19, 160-166.
34. VEELKEN, H., MACHENSEN, A., LAHN, M., KOHLER, G., BECKER, D., FRANKE, D., BRENNSCHEIDT, U., KULMBURG, P., ROSENTHAL, F.M., KELLER, H., HASSE, J., SCHULTZE-SEEMAN, W., FARTHMAN, E.H., MERTELSMAN, R., and LINDERMAN, A. (1997). A phase 1 clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer. Int. J. Cancer 70, 263-277.
35. CLARY, B.M., COVENEY, E.C., BLAZER, D.G., PHILIP, R., and LYERLY, H.K. (1996). Active immunotherapy of pancreatic cancer with tumor cells genetically engineered to secrete multiple cytokines. Surgery 120, 174-181.
36. PARKER, S.E., KHATIBI, S., MARGALITH, M., ANDERSON, D., YANKAUCKAS, M., GROMKOWSKI, S.H., LATIMER, T., LEW, D., MARQUET, M., MANTHROPE, M., HOBART, P., HERSH, E., STOPECK, A.T., and NORMAN, J. (1996). Plasmid DNA gene therapy: studies with the human interleukin-2 gene in tumor cells in vitro and in the murine melanoma model in vivo. Cancer Gene Ther. 3, 175-185.
37. XIANG, Z., and ERTL, H.C. (1995). Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 2, 129-135.
38. CHOW, Y.-H., HUANG, W.-L., CHU, Y.-D., CHI, W.-K., and TAO, M.-H. (1997). Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. J. Virol. 71, 169-178.
39. TUNG, C., FEDEROFF, H.J., BROWNLEE, M., KARPOFF, H., WEIGEL, T., BRENNAN, M.F., and FONG, Y. (1996). Rapid production of interleukin-2-secreting tumor cells by herpes simplex virus-mediated gene transfer: implications for autologous vaccine production. Hum. Gene Ther. 7, 2217-2224.
40. TOLOZA, E.M., HUNT, K., SWISHER, S., McBRIDE, W., LAU, R., PANG, S., RHOADES, K., DRAKE, T., BELLDEGRUM, A., GLASPY, J., and ECONOMOU, J.S. (1996). In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector. Cancer Gene Ther. 3, 11-17.
41. TOLOZA, E.M., HUNT, K., MILLER, A.R., McBRIDE, W., LAU, R., SWISHER, S., RHOADES, K., ARTHUR, J., CHOI, J., CHEN, L., CHANG, P., CHEN, A., GLASPY, J., and ECONOMOU, J.S. (1997). Transduction of murine and human tumors using recombinant adenovirus vectors. Ann. Surg. Oncol. 4, 70-79.
42. HEIKE, Y., TAKAHASHI, M., KANAGAE, Y., SATO, Y., SAITO, I., and SAIJO, N. (1997). Interkukin-2 gene transduction into freshly isolated lung adenocarcinoma cells with adenoviral vectors. Hum. Gene Ther. 8, 1-14.
43. OKADA, H., MIYAMURA, K., ITOH, T., HAGIWAR, M., WAKABAYASHI, T., MIZUUNO, M., COLOSI, P., KURTZMAN, G., and YOSHIDA, J. (1996). Gene therapy against an experimental glioma using adeno-associated virus vectors. Gene Ther. 3, 957-964.
44. CAO, G., KURIYAMA, S.D.P., SAKAMOTO, T., YANG, W., MASUI, K., and QI, Z. (1996). Construction of retroviral vectors to induce strong hepatoma cell specific expression of cytokine genes. J. Gastroenterol. Hepatol. 11, 1053-1061.
45. GUNDLACH, B.R., LINHART, H., DITTMER, U., SOPPER, S., REIPRICH, S., FUCHS, S., FLECKENSTEIN, B., HUNSMAN, G., STAHL-HENNING, C., and UBERLA, K. (1997). Construction, replication, and immunogenic properties of a simian immunodeficiency virus expressing interleukin-2. J. Virol. 71, 2225-2232.
46. KATSANIS, E., ORCHARD, P.J., BAUSERO, M.A., GORDEN, K.B., McIVOR, R.S., and BLAZAR, B.R. (1994). Interleukin-2 gene transfer into murine neuroblastoma decreases tumorigenicity and enhances systemic immunity causing regression of preestablished retroperitoneal tumors. J. Immunol. 15, 81-90.
47. LEONG, K.H., RAMSEY, A.J., BOYLE, D.B., and RAMSHAW, I.A. (1996). Selective induction of immune responses by cytokines coexpressed in recombinant fowlpox virus. J. Virol. 68, 8125-8130.
48. OIN, H., and CHATTERJEE, S.K. (1996). Recombinant vaccinia expressing interleukin-2 for cancer gene therapy. Cancer Gene Ther. 3, 163-167.
49. KAWAKITA, M., RAO, G.S., RITCHEY, J.K., ORNSTEIN, D.K., HUDSON, M.A., TARTAGLIA, J., PAOLETTI, E., HUMPHREY, P.A., HARMON, T.J., and RATLIFF, T.L. (1997). Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostrate tumor growth. J. Natl. Cancer Inst. 89, 428-436.